mRNA Pipeline
Research
Browse:
Our mRNA pipeline shows the progress we’re making on clinical programs currently in development to create mRNA medicines for a wide range of diseases and conditions.
as-of November 6, 2025
Please click here for more information on our approved products
All Categories
Program Indication
ID #
Preclinical Development
Phase 1
Phase 2
Phase 3
Commercial
Partner
Respiratory Vaccines
Adults
COVID-19 vaccine
SPIKEVAX®
Commercial
Partner:
COVID-19 vaccine
mNEXSPIKE®
Commercial
Partner:
Flu vaccine
mRNA-1010
Phase 3
Partner:
RSV vaccine
mRESVIA®
Commercial
Partner:
Flu + COVID vaccine
mRNA-1083
Phase 3
Partner:
Pandemic Flu vaccine
mRNA-1018
Phase 2
Partner:
RSV + hMPV vaccine
mRNA-1365
Phase 1
Partner:
Adolescents and Pediatrics
COVID-19 vaccineadolescents
SPIKEVAX®
Commercial
Partner:
RSV vaccinepediatrics
mRNA-1345
Phase 2
Partner:
Latent & Other Vaccines
Latent Viruses
CMV vaccinefor transplant recipients
mRNA-1647
Phase 2
Partner:
EBV vaccineto prevent infectious mononucleosis
mRNA-1189
Phase 2
Partner:
EBV vaccineto address long term EBV sequelae
mRNA-1195
Phase 2
Partner:
HSV vaccine
mRNA-1608
Phase 2
Partner:
VZV vaccine
mRNA-1468
Phase 2
Partner:
HIV vaccine
mRNA-1644
Phase 1
Partner:IAVI
Enteric Viruses
Norovirus vaccine
mRNA-1403
Phase 3
Partner:
Norovirus vaccine
mRNA-1405
Phase 2
Partner:
Bacterial Vaccines
Lyme disease vaccine
mRNA-1975
Phase 2
Partner:
Lyme disease vaccine
mRNA-1982
Phase 2
Partner:
Public Health
Nipah vaccine
mRNA-1215
Phase 1
Partner:NIH
Mpox vaccine
mRNA-1769
Phase 1
Partner:
Therapeutics
ONCOLOGY - Intismeran autogene
Adjuvant melanoma
mRNA-4157
Phase 3
Partner:Merck
Adjuvant NSCLC
mRNA-4157
Phase 3
Partner:Merck
Adjuvant NSCLC non-pCR post neoadjuvant treatment
mRNA-4157
Phase 3
Partner:Merck
Renal cell carcinoma (RCC)
mRNA-4157
Phase 2
Partner:Merck
Bladder cancer (HR MIUC)
mRNA-4157
Phase 2
Partner:Merck
Bladder cancer (HR NMIBC)
mRNA-4157
Phase 2
Partner:Merck
Metastatic melanoma
mRNA-4157
Phase 2
Partner:Merck
First-line metastatic squamous NSCLC
mRNA-4157
Phase 2
Partner:Merck
Early and advanced solid tumors
mRNA-4157
Phase 1
Partner:Merck
ONCOLOGY - CANCER ANTIGEN THERAPIES
Advanced solid tumors
mRNA-4359
Phase 2
Partner:
Solid tumors
mRNA-4106
Phase 1
Partner:
ONCOLOGY - T-CELL ENGAGERS
Multiple myeloma
mRNA-2808
Phase 1
Partner:
ONCOLOGY - CELL THERAPY ENHANCERS
Solid tumors
mRNA-4203 + anzu-cel (IMA-203)
Preclinical Development
Partner: Immatics
Rare Disease Intercellular Therapeutics
Propionic acidemia (PA)
mRNA-3927
Phase 2
Partner:
Methylmalonic acidemia (MMA)
mRNA-3705
Phase 2
Partner:
Glycogen Storage Disease Type 1a (GSD1a)
mRNA-3745
Phase 1
Partner:
Ornithine transcarbamylase deficiency (OTC)
mRNA-3139
Preclinical Development
Partner:
Crigler-Najjar Syndrome Type 1 (CN-1)
mRNA-3351
Preclinical Development
Partner:ILCM
Cystic fibrosis (CF)
mRNA-3692 / VX-522
Phase 1
Partner:Vertex
Abbreviations: NSCLC, non-small cell lung cancer; HR MIUC, high-risk muscle-invasive urothelial carcinoma; HR NMIBC, high-risk non-muscle invasive bladder cancer
as-of November 6, 2025
Please click here for more information on our approved products